Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with I-MIP-1095.

MLA

Afshar-Oromieh, Ali, et al. “Repeated PSMA-Targeting Radioligand Therapy of Metastatic Prostate Cancer with I-MIP-1095.” European Journal of Nuclear Medicine & Molecular Imaging, vol. 44, no. 6, June 2017, pp. 950–59. EBSCOhost, https://doi.org/10.1007/s00259-017-3665-9.

APA

Afshar-Oromieh, A., Haberkorn, U., Zechmann, C., Armor, T., Mier, W., Spohn, F., Debus, N., Holland-Letz, T., Babich, J., & Kratochwil, C. (2017). Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with I-MIP-1095. European Journal of Nuclear Medicine & Molecular Imaging, 44(6), 950–959. https://doi.org/10.1007/s00259-017-3665-9

Chicago

Afshar-Oromieh, Ali, Uwe Haberkorn, Christian Zechmann, Thomas Armor, Walter Mier, Fabian Spohn, Nils Debus, Tim Holland-Letz, John Babich, and Clemens Kratochwil. 2017. “Repeated PSMA-Targeting Radioligand Therapy of Metastatic Prostate Cancer with I-MIP-1095.” European Journal of Nuclear Medicine & Molecular Imaging 44 (6): 950–59. doi:10.1007/s00259-017-3665-9.